2025
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation
Sweeney S, Laurence Y, Berry C, Singh M, Dodd M, Fielding K, Kazounis E, Moodliar R, Solodovnikova V, Tigay Z, Liverko I, Parpieva N, Butabekov I, Usmanova R, Rassool M, Motta I, Nyangweso G, Jolivet P, Abdrasuliev T, Moe S, Aw P, Samieva N, Nyang'wa B. 24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. The Lancet Global Health 2025, 13: e355-e363. PMID: 39890235, DOI: 10.1016/s2214-109x(24)00467-4.Peer-Reviewed Original ResearchConceptsStandard of careRifampicin-resistant tuberculosisPatient-incurred costsHealth systemStandard-of-care regimensTreatment of rifampicin-resistant tuberculosisWeeks of follow-upAll-oral regimensReduce pill burdenImprove treatment efficacyTuberculosis treatment regimensCost-savingProbabilistic sensitivity analysesBurden of tuberculosisEconomic evaluationDegrees of cost savingsInpatient bed daysTrial-based evidenceEfficacy endpointCost dataRegimen groupPill burdenDrug regimensTreatment regimensUnfavourable outcomeDirect oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials.
Jenab Y, Sadeghipour P, Mohseni-Badalabadi R, Kaviani R, Hosseini K, Pasebani Y, Khederlou H, Rafati A, Mohammadi Z, Jamalkhani S, Talasaz A, Firouzi A, Ariannejad H, Alemzadeh-Ansari M, Ahmadi-Renani S, Maadani M, Farrashi M, Bakhshandeh H, Piazza G, Krumholz H, Mehran R, Lip G, Bikdeli B. Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials. EuroIntervention 2025, 21: 82-92. PMID: 39773831, PMCID: PMC11684328, DOI: 10.4244/eij-d-24-00527.Peer-Reviewed Original ResearchConceptsST-elevation myocardial infarctionLeft ventricular thrombusLeft ventricular thrombus resolutionRandomised clinical trialsPooled analysisVentricular thrombusTreatment of left ventricular thrombusTwo-dimensional transthoracic echocardiographyMyocardial infarctionDirect oral anticoagulantsImaging core laboratoryWarfarin-based anticoagulationMeta-analysis of randomised trialsTransthoracic echocardiographyOpen-labelOral anticoagulantsBleeding eventsAdult patientsDOACsCore laboratoryWarfarinClinical trialsRandomised trialsPatientsBleeding
2024
Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidence
Mooghali M, Zhou T, Ross J. Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidence. BMJ Open 2024, 14: e090376. PMID: 39461853, PMCID: PMC11529451, DOI: 10.1136/bmjopen-2024-090376.Peer-Reviewed Original ResearchConceptsPhase 2 trialPhase 3 trialBox warningAtrial fibrillation patientsPostmarketing evidenceEvidence of safetyOral anticoagulantsFibrillation patientsPostmarketing studiesCross-sectional analysisDegree of concordanceStroke preventionStudy requirementsPostmarketingEfficacy evidenceRegulatory agenciesDrugPostmarketing requirementsInterpretation of resultsEfficacyHealth CanadaSample sizeSafety evidenceConcordanceEndpointA Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield G, Bowlus C, Mayo M, Kremer A, Vierling J, Kowdley K, Levy C, Villamil A, Ladrón de Guevara Cetina A, Janczewska E, Zigmond E, Jeong S, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado M, Bergheanu S, Yang K, Choi Y, Crittenden D, McWherter C. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. New England Journal Of Medicine 2024, 390: 783-794. PMID: 38381664, DOI: 10.1056/nejmoa2312100.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisAlkaline phosphatase levelsPruritus Numerical Rating ScalePercentage of patientsNumerical rating scaleBiliary cholangitisAdverse eventsPhosphatase levelsPlacebo groupUrsodeoxycholic acidPeroxisome proliferator-activated receptor delta agonistBaseline to month 6Severity of adverse eventsAlkaline phosphatase normalizationModerate-to-severe pruritusPlacebo-controlled trialPhase 3 trialUnacceptable side effectsRating ScaleBiochemical responsesBackground therapyDouble-blindDelta agonistsBilirubin levelsMonth 6Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients
Ranjan S, Leung D, Ghiaseddin A, Taylor J, Lobbous M, Dhawan A, Budhu J, Coffee E, Melnick K, Chowdhary S, Lu‐Emerson C, Kurz S, Burke J, Lam K, Patel M, Dunbar E, Mohile N, Peters K. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer 2024, 130: 1577-1589. PMID: 38288941, DOI: 10.1002/cncr.35220.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsBrain NeoplasmsHemorrhageHumansNeoplasm Recurrence, LocalNeoplasmsProspective StudiesVenous ThromboembolismConceptsDirect oral anticoagulantsLow-molecular-weight heparinVenous thromboembolismIntracranial hemorrhageBrain tumorsEfficacy of direct oral anticoagulantsMetastatic brain tumor patientsRisk of intracranial hemorrhageTreatment of venous thromboembolismManagement of venous thromboembolismMetastatic brain tumorsOral anticoagulant useTreat venous thromboembolismOff-label useBrain tumor patientsBrain metastasesOral anticoagulantsAnticoagulant useTumor patientsClinical trialsPatientsClinical guidanceThromboembolismGlioblastomaHeparinWhen Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review
Bejjani A, Khairani C, Assi A, Piazza G, Sadeghipour P, Talasaz A, Fanikos J, Connors J, Siegal D, Barnes G, Martin K, Angiolillo D, Kleindorfer D, Monreal M, Jimenez D, Middeldorp S, Elkind M, Ruff C, Goldhaber S, Krumholz H, Mehran R, Cushman M, Eikelboom J, Lip G, Weitz J, Lopes R, Bikdeli B. When Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2024, 83: 444-465. PMID: 38233019, DOI: 10.1016/j.jacc.2023.10.038.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsStandard of careRandomized controlled trialsOral anticoagulantsAtrial fibrillationCatheter-associated deep vein thrombosisCerebral venous sinus thrombosisControlled trialsVitamin K antagonistsThrombotic antiphospholipid syndromeEnd-stage renal diseaseLeft ventricular thrombusVenous thromboembolism treatmentVenous sinus thrombosisDeep vein thrombosisRheumatic heart diseaseReview of randomized controlled trialsEvidence-based reviewK antagonistsAntiphospholipid syndromeSinus thrombosisVentricular thrombusVein thrombosisThromboembolism treatmentVenous thrombosis
2023
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Kowdley K, Bowlus C, Levy C, Akarca U, Alvares-da-Silva M, Andreone P, Arrese M, Corpechot C, Francque S, Heneghan M, Invernizzi P, Jones D, Kruger F, Lawitz E, Mayo M, Shiffman M, Swain M, Valera J, Vargas V, Vierling J, Villamil A, Addy C, Dietrich J, Germain J, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein C, Schattenberg J. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. New England Journal Of Medicine 2023, 390: 795-805. PMID: 37962077, DOI: 10.1056/nejmoa2306185.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAlkaline PhosphataseBilirubinChalconesCholagogues and CholereticsCholestasisDouble-Blind MethodGastrointestinal AgentsHumansLiver Cirrhosis, BiliaryPeroxisome Proliferator-Activated ReceptorsPPAR alphaPPAR deltaPropionatesPruritusTreatment OutcomeUrsodeoxycholic AcidConceptsPrimary biliary cholangitisBiliary cholangitisAlkaline phosphatase levelsPeroxisome proliferator-activated receptorPhosphatase levelsDual peroxisome proliferator-activated receptorLeast-squares mean changeChronic cholestatic liver diseaseItch Numeric Rating ScaleDestruction of interlobular bile ductsModerate-to-severe pruritusPlacebo-controlled trialCholestatic liver diseaseNumerical rating scaleInterlobular bile ductsWorst Itch Numeric Rating ScaleIndicator of cholestasisProliferator-activated receptorsAbdominal painDouble-blindPlacebo groupRelevant biochemical indicatorsAdverse eventsPruritus intensityUrsodeoxycholic acidSingle-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Sacher A, LoRusso P, Patel M, Miller W, Garralda E, Forster M, Santoro A, Falcon A, Kim T, Paz-Ares L, Bowyer S, de Miguel M, Han S, Krebs M, Lee J, Cheng M, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin M, Royer-Joo S, Chang J, Dharia N, Schutzman J, Desai J. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. New England Journal Of Medicine 2023, 389: 710-721. PMID: 37611121, DOI: 10.1056/nejmoa2303810.Peer-Reviewed Original ResearchConceptsMedian progression-free survivalTreatment-related adverse eventsProgression-free survivalAdverse eventsSolid tumorsG12C mutationLow-grade adverse eventsGrade 3 eventsGrade 4 eventsTreatment-related deathsDiscontinuation of treatmentMetastatic solid tumorsPhase 1 studyDurable clinical responsesBiomarkers of responseKRAS G12C mutationAssessment of safetyVariant allele frequencyClinical responseColorectal cancerSerial assessmentDose reductionG12C inhibitorsPatientsTumor DNAGenetic Variation and Sensory Perception of a Pediatric Formulation of Ibuprofen: Can a Medicine Taste Too Good for Some?
Mennella J, Kan M, Lowenthal E, Saraiva L, Mainland J, Himes B, Pepino M. Genetic Variation and Sensory Perception of a Pediatric Formulation of Ibuprofen: Can a Medicine Taste Too Good for Some? International Journal Of Molecular Sciences 2023, 24: 13050. PMID: 37685855, PMCID: PMC10487938, DOI: 10.3390/ijms241713050.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralCohort StudiesDosage FormsGenetic VariationHumansIbuprofenPerceptionSensationTasteConceptsGenetic ancestryEuropean genetic ancestryTaste receptor genesIndependent of ancestryAfrican genetic ancestryGenetic variationFormulations of ibuprofenEpigenetic factorsAncestryReceptor geneDouble-blind cohort studyUrge to coughPerception of palatabilityRisk of accidental ingestionPersonality variationCohort studyPediatric formulationsSensory phenotypesThroat sensationChemesthetic sensationsMedicinal tasteTingling sensationPanelistsAdult panelistsDiverse populationsWeighing in on Direct Oral Anticoagulant Dosing in Patients With Obesity
Rosenfeld L. Weighing in on Direct Oral Anticoagulant Dosing in Patients With Obesity. The American Journal Of Cardiology 2023, 203: 501-502. PMID: 37517899, DOI: 10.1016/j.amjcard.2023.07.012.Peer-Reviewed Original ResearchRecent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke
Mac Grory B, Holmes D, Matsouaka R, Shah S, Chang C, Rison R, Jindal J, Holmstedt C, Logan W, Corral C, Mackey J, Gee J, Bonovich D, Walker J, Gropen T, Benesch C, Dissin J, Pandey H, Wang D, Unverdorben M, Hernandez A, Reeves M, Smith E, Schwamm L, Bhatt D, Saver J, Fonarow G, Peterson E, Xian Y. Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke. JAMA 2023, 329: 2038-2049. PMID: 37338878, PMCID: PMC10282891, DOI: 10.1001/jama.2023.8073.Peer-Reviewed Original ResearchConceptsRisk of sICHSymptomatic intracranial hemorrhageVitamin K antagonistsAcute ischemic strokeSecondary end pointsEndovascular thrombectomyVKA useIschemic strokeHospital mortalityEnd pointIntracranial hemorrhageOral vitamin K antagonistsVitamin K antagonist useGuidelines-Stroke programPrior VKA usePrimary end pointObservational cohort studyLarge vessel occlusionRisk of complicationsAmerican Heart AssociationUse of anticoagulantsSignificant differencesHospital presentationSICH riskAntagonist useZiritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
Maher T, Ford P, Brown K, Costabel U, Cottin V, Danoff S, Groenveld I, Helmer E, Jenkins R, Milner J, Molenberghs G, Penninckx B, Randall M, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins T, Wuyts W, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek M, Chambers D, Chia M, Corte T, Glaspole I, Goh N, Holmes M, Malouf M, Thien F, Veitch E, Bondue B, Dahlqvist C, Froidure A, Slabbynck H, Wuyts W, Cartagena Salinas C, Feijoó Seoane R, Martínez V, Maturana R, Pavie Gallegos J, Rosenblut A, Silva R, Undurraga Pereira A, Doubkova M, Pauk N, Plackova M, Sterclova M, Bendstrup E, Shaker S, Titlestad I, Budweiser S, Grohé C, Koschel D, Kreuter M, Prasse A, Weber M, Wirtz H, Antoniou K, Daniil Z, Gaga M, Papakosta D, Izumi S, Okamoto M, Guerreros Benavides A, Iberico Barrera C, Peña Villalobos A, Campo Ezquibela A, Cifrian Martinez J, Fernandez Fabrellas E, Leiro V, Molina-Molina M, Nieto Barbero A, Sellares Torres J, Valenzuela C, Cheng S, Kuo P, Lee K, Sheu C, Gunen H, Mogulkoc Bishop N, Nayci S, Adamali H, Bianchi S, Chaudhuri N, Gibbons M, Hart S, Molyneaux P, Parfrey H, Saini G, Spencer L, Wiscombe S, Antin-Ozerkis D, Bascom R, Belperio J, Britt E, Fitzgerald J, Gomez Manjarres D, Gotfried M, Gupta N, Hotchkin D, Kaye M, Kreider M, Kureishy S, Lacamera P, Lancaster L, Lasky J, Lorch D, Mannem H, Morrow L, Moua T, Nambiar A, Raghu G, Raj R, Ramaswamy M, Reddy R, Russell T, Scholand M, Shea B, Suliman S, Swigris J, Thavarajah K, Tolle L, Tomic R, Warshoff N, Wesselius L, Yung G, Bergna M, De Salvo M, Fernandez Acquier M, Rodriguez A, Saez Scherbovsky P, Assayag D, Dhar A, Khalil N, Morisset J, Provencher S, Ryerson C, Shapera S, Bourdin A, Crestani B, Lebargy F, Reynaud-Gaubert M, Bonella F, Claussen M, Hammerl P, Karagiannidis C, Keller C, Randerath W, Stubbe B, Csánky E, Medgyasszay B, Muller V, Adir Y, Bar-Shai A, Berkman N, Fink G, Kramer M, Shitrit D, Bargagli E, Gasparini S, Harari S, Ravaglia C, Richeldi L, Vancheri C, Ebina M, Fujita M, Ichikado K, Inoue Y, Ishikawa N, Kato M, Kawamura T, Kondoh Y, Nishioka Y, Ogura T, Owan I, Saito T, Sakamoto N, Sakamoto K, Shirai M, Suda T, Tomii K, Chung M, Jeong S, Park C, Park J, Song J, Uh S, Chavarria Martinez U, Montano Gonzalez E, Ramirez A, Selman Lama M, Bresser P, Kramer H, Mostard R, Nossent E, Veltkamp M, Wijsenbeek M, Beckert L, Chang C, Veale A, Wilsher M, Bednarek M, Gasior G, Jasieniak-Pinis G, Jassem E, Mroz R, Piotrowski W, Abdullah I, Ambaram A, Irusen E, Van der Linden M, van Zyl-Smit R, Williams P, Allen J, Averill F, Belloli E, Brown A, Case A, Chaudhary S, Criner G, DeBoer K, Dilling D, Dorf J, Enelow R, Ettinger N, Feldman J, Gibson K, Golden J, Hamblin M, Hunninghake G, Karunakara R, Kim H, Luckhardt T, Menon P, Morrison L, Oldham J, Patel N, Schmidt S, Strek M, Summer R, Sussman R, Tita J, Veeraraghavan S, Whelan T, Zibrak J. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis. JAMA 2023, 329: 1567-1578. PMID: 37159034, PMCID: PMC10170340, DOI: 10.1001/jama.2023.5355.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedClinical Trials, Phase III as TopicFemaleHumansIdiopathic Pulmonary FibrosisLungMaleMiddle AgedMulticenter Studies as TopicPhosphodiesterase InhibitorsQuality of LifeRandomized Controlled Trials as TopicRespiratory Physiological PhenomenaRespiratory System AgentsTreatment OutcomeConceptsIdiopathic pulmonary fibrosisKey secondary outcomesFVC declineSecondary outcomesPulmonary fibrosisCare treatmentSt George's Respiratory Questionnaire (SGRQ) total scoreRespiratory-related hospitalizationsSafety Monitoring CommitteeQuestionnaire total scoreNovel autotaxin inhibitorAnnual rateCause mortalityWeek 52Lung functionPrimary outcomeClinical outcomesVital capacityStudy terminationClinical trialsDisease progressionPlaceboMAIN OUTCOMEPatientsAutotaxin inhibitorsPrednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization
Sun Y, Cui L, Lu Y, Tan J, Dong X, Ni T, Yan J, Guan Y, Hao G, Liu J, Zhang B, Wei D, Hong Y, He Y, Qi J, Xu B, Lu J, Zhang Q, Zhao S, Ji X, Du X, Zhang J, Liu J, Wang J, Huang Y, Huang D, Du Y, Vankelecom H, Zhang H, Chen Z. Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization. JAMA 2023, 329: 1460-1468. PMID: 37129654, PMCID: PMC10155063, DOI: 10.1001/jama.2023.5302.Peer-Reviewed Original ResearchConceptsRecurrent implantation failureFrozen-thawed embryo transferBiochemical pregnancy lossLive birthsImplant failurePlacebo groupPrednisone groupPreterm deliveryEmbryo transferPregnancy lossRisk of preterm deliveryRates of biochemical pregnancyEmbryo transfer cyclesGood-quality embryosLive birth rateLive birth outcomesTreatment of recurrent implantation failureStatistically significant between-group differencesHistory of 2Randomized clinical trialsProbability of implantationImmune-regulatory agentSignificant between-group differencesNeonatal complicationsWeeks gestationIdentifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method
Ngufor C, Yao X, Inselman J, Ross J, Dhruva S, Graham D, Lee J, Siontis K, Desai N, Polley E, Shah N, Noseworthy P, MN; New Haven C. Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. American Heart Journal 2023, 260: 124-140. PMID: 36893934, PMCID: PMC10615250, DOI: 10.1016/j.ahj.2023.02.015.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAnticoagulantsAtrial FibrillationDabigatranFemaleHumansIschemic StrokePyridonesRivaroxabanStrokeWarfarinConceptsOral anticoagulantsAtrial fibrillationPatient subgroupsComposite outcomeIschemic strokeEffect of OACsLifelong oral anticoagulationNonvitamin K antagonistNew oral anticoagulantsNonvalvular atrial fibrillationPrimary composite outcomeGlomerular filtration rateFuture prospective studiesOptumLabs Data WarehousePopulation-level effectivenessOAC useOral anticoagulationVASc scoreCause mortalityK antagonistsPrimary endpointWarfarin usersRenal functionAF patientsEntire cohortFactor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Park D, An S, Arif A, Sana M, Vij A. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2023, 23: 100. PMID: 36814196, PMCID: PMC9945392, DOI: 10.1186/s12872-023-03067-4.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsFactor Xa InhibitorsFibrinolytic AgentsHemorrhageHumansObesity, MorbidVenous ThromboembolismConceptsClinically relevant non-major bleedingNon-vitamin K antagonist oral anticoagulantsVitamin K antagonistsMorbidly obese patientsRecurrent venous thromboembolismObese patientsVenous thromboembolismFactor Xa inhibitorsK antagonistsXa inhibitorsTreating morbidly obese patientsVitamin K antagonist groupNon-major bleedingMeta-analysisTreat venous thromboembolismMeta-analysis of studiesHigh-risk populationAssociated with lower oddsRandomized controlled trialsOral anticoagulantsGoogle Scholar databasesMorbid obesityNo significant differenceLandmark trialsAtrial fibrillationValidated anxiety assessments among pediatric patients with peanut allergy on oral immunotherapy
Kaman K, Dhodapkar M, Shabanova V, McCollum S, Factor J, Leeds S. Validated anxiety assessments among pediatric patients with peanut allergy on oral immunotherapy. Annals Of Allergy Asthma & Immunology 2023, 130: 657-663. PMID: 36738780, DOI: 10.1016/j.anai.2023.01.028.Peer-Reviewed Original ResearchConceptsPeanut oral immunotherapyOral immunotherapyNon-white racePeanut allergyAnxiety scoresOlder cohortProspective cross-sectional cohort studyCross-sectional cohort studyHigher mean anxiety scoresMean anxiety scoreDiagnosable anxietyCohort studyMale patientsPediatric patientsFemale patientsFood allergySimilar patientsHigh prevalenceHigher scoresLife measuresLow prevalencePatientsSeparation anxiety scoresElectronic survey questionnaireAllergy
2022
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma
Shayeb A, McManus H, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan C, Barata P, Bilen M, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan M, McGregor B, Choueiri T, McKay R. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 21: 55-62. PMID: 36411184, DOI: 10.1016/j.clgc.2022.10.013.Peer-Reviewed Original ResearchConceptsLow molecular weight heparinRenal cell carcinomaMajor bleeding eventsBleeding eventsRecurrent VTECell carcinomaDirect oral anticoagulant useAdvanced renal cell carcinomaDifferent anticoagulantsPrimary safety endpointSafety of cabozantinibOral anticoagulant usePrimary efficacy endpointClear cell histologyReal-world cohortRetrospective multicenter studyRisk-benefit discussionsLimited safety dataVenous thromboembolism managementMolecular weight heparinAnticoagulant groupConcurrent anticoagulationDOAC groupThrombosis complicationsEfficacy endpointDirect Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials
Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller S, Cortes-Hernandez J, Connors J, Kanthi Y, Krumholz H, Middeldorp S, Falanga A, Cushman M, Goldhaber S, Garcia D, Bikdeli B. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2022, 81: 16-30. PMID: 36328154, PMCID: PMC9812926, DOI: 10.1016/j.jacc.2022.10.008.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsVitamin K antagonistsVenous thromboembolic eventsArterial thrombotic eventsSubsequent venous thromboembolic eventsThrombotic antiphospholipid syndromeMajor bleedingThrombotic eventsK antagonistsOral anticoagulantsAntiphospholipid syndromeUse of DOACsMain efficacy outcomeMain safety outcomeCochrane Central RegisterAdequate allocation concealmentRandom-effects modelRandom sequence generationThromboembolic eventsCentral RegisterEfficacy outcomesArterial thrombosisControlled TrialsRandomized trialsAllocation concealmentOral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis.
Blinder VS, Garrett-Mayer E, Jacobsen PB, Kozlik MM, Markham MJ, Siegel RD, Kamal AH, Crist STS, Rosenthal J, Chiang AC, _ _. Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis. Journal Of The National Comprehensive Cancer Network 2022, 20: 1099-1106.e2. PMID: 36240846, DOI: 10.6004/jnccn.2022.7024.Peer-Reviewed Original ResearchClinical and neuroimaging risk factors associated with the development of intracerebral hemorrhage while taking direct oral anticoagulants
Das A, Gökçal E, Regenhardt R, Warren A, Biffi A, Goldstein J, Kimberly W, Viswanathan A, Schwamm L, Rosand J, Greenberg S, Gurol M. Clinical and neuroimaging risk factors associated with the development of intracerebral hemorrhage while taking direct oral anticoagulants. Journal Of Neurology 2022, 269: 6589-6596. PMID: 35997817, PMCID: PMC10947801, DOI: 10.1007/s00415-022-11333-2.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsCerebral HemorrhageHumansIschemic StrokeMagnetic Resonance ImagingNeuroimagingRisk FactorsSiderosisConceptsCortical superficial siderosisPrior ischemic strokeDOAC usersCerebral microbleedsWhite matter hyperintensitiesIschemic strokeSevere white matter hyperintensitiesOral anticoagulant usageDirect oral anticoagulantsSingle referral centerHigh hemorrhagic riskCoronary artery diseaseAge-matched controlsMultivariable regression modelsDOAC therapyICH cohortPrior strokeOral anticoagulantsSuperficial siderosisBaseline demographicsReferral centerSmoking historyArtery diseaseConclusionsRisk factorsHemorrhage risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply